Vaccination hesitancy and the “myth” on mRNA-based vaccines in Italy in the COVID-19 era: Does urgency meet major safety criteria?

Salvatore Chirumbolo

Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy

Correspondence
Salvatore Chirumbolo, PhD, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Strada Le Grazie 9 37134 Verona, Italy.
Email: salvatore.chirumbolo@univr.it

Abstract
Coronavirus disease 2019 (COVID-19) vaccination campaign in Italy has started with a huge perplexity about vaccine efficacy, vaccine-borne adverse effects and vaccine clinical trial studies. In this commentary I tried to elucidate these issues, which represent a fundamental topic to be thoroughly addressed in COVID-19 pandemic.

KEYWORDS
administrative law, coronavirus, political science, public policy, social science, virus classification

1 BACKGROUND

Coronavirus disease 2019 (COVID-19) pandemic still stands as a huge health concern, reaching more than 2.61 millions of cases and 90,618 victims worldwide on February 5th, 2021. To face at pandemic emergency, any Government is engaging a gigantic struggle against infectious contacts. Nations are currently adopting lockdown and several restrictions measures against usual social habits but are more frequently asking for crucial and urgent decisions from politics in setting the widest vaccination campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anyway, despite vaccination emergency is somewhat felt as a mandatory commitment to dampen infectious contacts, reduce COVID-19 hospitalization and come back to previous life customs, vaccination hesitancy, particularly on the more straightforward messenger RNA (mRNA)-based vaccines, still represents a fundamental concern.

In Italy, particularly for people usually refusing flu vaccines, hesitancy towards novel vaccine mRNA formulas is closely associated with increasing doubts on vaccination in general. By the way, public and institutional information about the many safety issues in the vaccination campaign are particularly weak in their persuasive potential. Questions were raised, for the many vaccine formulations available to date, on who could be vaccinated or not without any major health risk, such as elderly people with co-morbidities or people living with HIV. The great complexity of topics regarding COVID-19 vaccines should deserve particular attention, as it deals with a global extent. Experts in the field focus their major concerns on allergy side effects and vaccination efficacy. For example, the ARIA-EAACI position paper about possible adverse effects caused by COVID19 vaccination, such as hypersensitivity reactions, recently stated that, as regarding the vaccine BNT162b2, several cases of anaphylaxis occurred, but the Committee concluded that vaccination, held to overcome pandemic, is much more crucial than risking for anecdotic episodes of severe anaphylaxis. This position statement may sound as a cynic consideration about safety, yet the urgency in defeating COVID-19 pandemic is considered of the utmost importance.

The critical controversy between urgency in dampening SARS-CoV-2 infections and vaccine reliability is the real matter of debate about vaccination.

The mRNA based BNT162b2 vaccine has been recently questioned about its efficacy against SARS-CoV-2 variants, despite very recent reports showed neutralization efficacy on N501Y nCOV19 mutant and the UK variant. Actually, mRNA based vaccines represent a straightforward tool against infectious diseases and pandemic. Widespread information about novel formulations, as mRNA-based vaccines, is particularly crowded and inflated by non
reviewed opinions and the debate can generate even alarming fakes about vaccination due to anecdotal news. As a matter of fact, people are commonly impressed by the emphasized tale of single, sporadic cases of adverse effects, without being correctly informed about the actual risk to undergo a severe damage upon a medical intervention. Estimating a risk to meet an adverse drug reaction (ADR) to vaccines, even by the mainstream information, is particularly crucial to warrant for a consolidated awareness of vaccination primacy among people. Whereas the US CDC reported 6 cases of anaphylaxis due to COVID-19 mRNA vaccines on 270,001 doses (Dec 19th, 2020), suggesting a risk <0.0023%, citizens could be ensured that this risk is really negligible in medical practice. Actually, undergoing a surgical intervention has a much higher mortality rate (0.71%) and 0.17% in elective surgery (10 times higher during emergency).15 On the contrary, the most correct information about vaccination is quite scanty in Italy, which prefers to mythologize COVID-19 vaccines as undisputable tools for health and well being, without any expanded debate about experts.16 Vaccine myth as well as vaccine distrust, are both regrettable attitudes.

A proper behavior towards vaccination is trusting vaccination as a medical expert practice and an outstanding and straightforward way to overcome infectious diseases. Trusting medicine should be a commonly positive feeling. Usually, a patient does not exhibit such burden of doubts and refusal against a simple therapeutic drug, despite even a simple pill, such as an antibiotic, may have adverse effects. The atavistic fear against vaccines dates back to Jenner, in the XVIII century, therefore, as people are convinced about vaccines as a source of “modified” harmful pathogens (yet, always pathogens) the concern of public vaccination is still far to be fully reassured.17

Therefore, which is the best approach to overcome this concern? To be much more properly and clearly informed.

2 | THE CURRENT DEBATE ABOUT COVID-19 MRNA VACCINES

In Italy, correct information about mRNA-based vaccines is scanty. Urgency in vaccination should not dampen the scientific debate. Both BNT-162b2, produced by Pfizer-BioNTech and mRNA-1273 by Moderna, are simple molecules of ribonucleic acid, modified with pseudo-uridine (9U) and included in lipid nano-particle (LNPs) vehicles. RNA is endowed to be rapidly translated into nonfunctional SARS-CoV-2 S (spike) proteins, i.e. an S-proteins in a stable closed structure,18 so to trigger the immune response in the host without inducing damage due to its activity on the ACE2 receptor.18,19 As reported few lines ago, recent data are supporting the idea that these vaccine formulations have possible and significant adverse effects, particularly by highlighting the worrisome concern that anaphylaxis due to BNT162b1 vaccine accounts to 1:45,000, a ratio much higher than the usual allergic side effect percentage due to commonly used vaccines, that is, 1:1,000,000.20 Estimated percentages need reappraisal on a global scale, however.

Briefly speaking, it is correct to state that some components should deserve caution, due to their assessed allergenicity.

Lipids used for LNPs may elicit allergy-related and immune responses.21,22 High molecular weight poly-ethylene-glycol, present in BNT162b2 as ALC0159 (2-(polyethylene glycol)-2000)-N,N-di-tetradecyl-acetamide) is considered the leading cause of vaccine-caused anaphylaxis.23 PEG presence, particularly in LNPs, is not yet a novelty in pharmacological science, anyway. PEG is contained in many commonly used medicines. Table 1 lists some major FDA approved drugs for human therapy, which contain PEG and may cause anaphylaxis. Considering that PEG is particularly frequent in several therapeutic formulas, the simple information about the anaphylactic potential of PEG should not exacerbate the civil debate about vaccines, at least because a huge deal of PEGylated therapeutic drugs is currently used in the medical healthcare without bursting raw popular outrages. More correct information to ensure citizens about vaccine safety is mandatory, therefore. Considering the small number of anaphylaxis cases in US by CDC reports and the amount of ADrs to vaccine in US (101) on 158,000 vaccinated people,24 the relative risk we calculated in our labs (SPSS software v 24.1) to meet a PEG-related anaphylaxis should be around 0.03, a very low value, even assessing previously reported evidence.25 Yet, reports exist showing that PEG-caused anaphylaxis may be particularly dramatic for subjects,23 and this may burst a serious public health concern.

In Italy, no clear warning about PEG-mediated ADRs regarding RNA-based vaccines has been ever forwarded by Government institutions, Scientific Committees or mainstream information, at least to organize a proper anti-anaphylaxis task force in the healthcare units. A sort of naïve mysticism around vaccination with BNT182b2 vaccine, as the only safe escape from restrictions to the social daily life and COVID-19 pandemic, has overcome any intelligent and moderate debate about the COVID-19 vaccination campaign.26 The concerning results of this sort of misleading information about RNA-based vaccines is the high degree of vaccine hesitancy in the Italian population reached so far.27 Common citizens, that is, people not engaged in healthcare jobs or medical activities, represent about a fifth (136,052 vs. 681,057) of the currently vaccinated Italian population: this rate is about one-third of the pro-vax people, that is, those individuals who trust vaccination as a safe way to rescue one’s own wellbeing and health (data on January 13th 2021 from Ministry of Health, Italy).

Pandemic should revise our own attitude towards vaccination, at least theoretically. A study performed in China on 806 nurses during the period February 26th to March 31st, 2020, showed that more nurses changed their personal beliefs about vaccination from refusal/hesitancy to acceptance, respect to refusing or hesitant colleagues, that is, 15.5% versus 6.89% (p < .001) and 40% participants expressed a clear intention to accept a possible COVID-19 vaccine, if promptly available.28 To date, though standing the availability of a straightforward vaccine formulation against COVID-19, the attitude has been quite reversed in the majority of people having experienced COVID-19 pandemic on their own lives.29 Some reasons appear to elucidate how come many health professionals are critical towards
TABLE 1  List of major PEGylated drugs approved by FDA in 2020 and their allergic effects

| Active principle                        | Drug commercial name                      | Company          | Therapeutic use                  | Examples of reports showing allergic and adverse effects |
|-----------------------------------------|-------------------------------------------|------------------|----------------------------------|---------------------------------------------------------|
| Recombinant anti-hemophilic factor      | Esperoct Turoctocog Alfa                  | Novo Nordisk Novoeight | Haemophilia A                    | Pires S et al., BMJ Case Rep. 2018 Dec 14:11(1):e227426. |
|                                          | Ziestenzo (Pegfilmgrastim)                | Sandoz           | Treating neutropenia during chemotherapy | Bustillo I, et al., Cutan Ocul Toxicol. 2009;28(4):181-4. |
|                                          | Palynziq (Pegvaliase)                     | BioMarin Pharmaceuticals | Phenylketonuria             | Hanna GG, et al., Clin Oncol (R Coll Radiol). 2008 May;20(4):315-6 |
|                                          | l-Asparaginase                           | Servier Pharma   | Leukemia                        | Fabry U et al., Pediatr Res. 1985 Apr;19(4):400-8. |
| Recombinant coagulation factor IX       | Rebinyn                                  | Novo Nordisk     | Hemophilia B                    | Levy-Mendelowich S et al., Blood Cells Mol Dis. 2020 Feb;80:102370. |
| Recombinant anti-hemophilic factor      | Adinovate                                | Baxalta          | Hemophilia A                    |                                                        |
| PEGylated IFN-α                         | Sylatron Peginterferon-alpha-2b          | Merck            | Melanoma                        | Meller S et al., Allergy. 2015 Jul;70(7):775-83. |
| Anti-TNF-α                              | Cinzia (Cerulizumab-pegol)               | UCB              | Rheumatoid arthritis            | McCabe E et al., Rheumatology (Oxford). 2020 Apr 1;59(4):908-910. |
| HGH (human growth hormone)              | Somavert (Pegvisomant)                   | Pfizer           | Acromegaly                      | Dadzie DD et al. Pituitary. 2012 Dec;15 Suppl 1:568-71 |

Abbreviations: G-CSF, granulocyte colony-stimulating factor; INF, interferon; TNF, tumor necrosis factor.
the novel vaccines against COVID-19 made of a PEGylated LNP-encapsulated mRNA: (a) a too much shortening the scheduled clinical trial phases; (b) lacking of prospective studies about vaccine ADRs on a longest time interval.

So, how hesitancy is still present? This can be due to scarcely monitored information.

The complex issue of vaccinology, particularly during a worldwide emergency, should be taken into account as a fundamental educational mission for public health. For example, criticisms should be discussed within the exclusive realm of the expert community. Notwithstanding, some news, of commercial impact, reach the widest community, generating false expectations. The purported 95% efficiency of mRNA-based vaccines has been deeply criticized.30,31 Doshi’s criticism raised against Pfizer-BioNTech and Moderna vaccines, on January 4th, 2021, regarded the reliability of data reported elsewhere.18,19 Despite mRNA technology for vaccine is a highly validated as excellent approach,10–14 one of Doshi’s major criticism regards the observations that the number of recruited subjects for clinical trials were dwarfed by a significant amount of participants diagnosed as COVID-19 positive on the simple basis of symptomology, as they were not polymerase chain reaction (PCR) confirmed, a number as high as 3410 total case, 1594 in the vaccine group and 1,816 in the placebo.31 Doshi will expand this consideration in a post dated February 5th, 2021 but his criticism, based on a FDA’s report on Pfizer’s vaccine, recalculated the Comirnaty, that is, BNT162b2 vaccine efficacy, around 19%–29%, instead of 95%.31

3 | HASTY VACCINE, BAD VACCINE?

Doshi recalculated BNT162b2 efficiency and therefore, besides to the many critical comments reported elsewhere about immunity, ethical abuse and ADRs,32,33 the quite hasty way by which the Pfizer-BioNTech vaccine was tested, due to the pandemic emergency, may reduce its purported and declared efficiency from 95% to a more real 29%.34 One of the more concerning issue regarding these innovative, straightforward vaccines based on an mRNA approach, is the lacking of prospective surveys. These studies are mandatory not only to verify possible non immediate ADRs due to the innovative technique used for vaccination but also for the immune coverage within the population. In a recent paper, some authors analyzed 3296 subjects for plasma presence of COVID-19 IgGs and only 243 individuals (7.43%) have detectable SARS-CoV-2 IgGs in the serum.35 Only 8 of them developed COVID-19 symptoms 30 days later, were SARS-CoV-2 RT-PCR positive but seven of them lost the specific IgGs.34–36

So, besides to ADRs, the biggest burden of concerns regarding mRNA-based vaccines is the complete lacking of prospective studies. This can be comprehensible, if we would like to shut down pandemic worldwide: vaccines are an undelayable emergency need. Two main issues should make highly debating the need to set a prospective survey. The LNP-encapsulated mRNA has been never attempted before as a vaccine tool and none can say anything about the consequences of introducing RNA inside the body. The increased ability of pseudouridinylated BNT162b2 mRNA or of mRNA1273 to be translated with relatively high efficiency, may cause endoplasmic reticulum stress (ER-stress) and an upregulation in chemokines mRNA because of a huge production of SARS-CoV-2 Spike (S) proteins.37 However, ribonucleases (RNases) are highly conserved enzymes that exist intra-cellularly and extracellularly with high abundance. These RNases can rapidly and effectively degrade mRNAs, thereby eliminating long-term side effects of mRNA vaccines, at least theoretically.

Although this evidence regards SARS-CoV, the concern has never been raised so far. In this perspective it could be particularly hard to distinguish if a chemokines-induced inflammatory burst may come from a very recent SARS-CoV-2 infection or from vaccination.38 Moreover, many criticisms were raised about the vaccine administration practice. A huge deal of misinformation, even regarding vaccine dosage, practice and temperature, might worse the delay with which people should be vaccinated.39 The hasty expectation to see brilliant outcomes following vaccination crushes against the paroxysmal crowd of objections.

4 | CONCLUSION

Which could be a conclusive remark of our debate herein reported? Outcry against vaccination, held by "scared" people, who are already stressed by pandemic caused fears, may be a real concern for any vaccination campaign, particularly if associated with long lasting hesitant and refusal attitudes of some individuals towards vaccination. Experts must be invited and encouraged, for ethical reasons, to build up a global task force with educational aims, to make aware people of what vaccination may contribute in rendering our world much more pleasant and addressable.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.
TECHNICAL REPORT

Efficacy of mRNA COVID-19 Vaccines: A Review of the Literature

Salvatore Chirumbolo

ORCID
Salvatore Chirumbolo http://orcid.org/0000-0003-1789-8307

REFERENCES

1. Paltiel AD, Zheng A, Schwartz JL. Speed versus efficacy: quantifying potential tradeoffs in COVID-19 vaccine deployment. Ann Intern Med. 2021;M20:7866. https://doi.org/10.7326/M20-7866
2. Barnabas RV, Wald A. A public health COVID-19 vaccination strategy to maximize the health gains for every single vaccine dose. Ann Intern Med. 2021;M20:8060. https://doi.org/10.7326/M20-8060
3. Puri N, Coomes EA, Haghayhani H, Gavaruzzi T. Associations of COVID-19 risk perception with vaccine hesitancy over time for Italian residents. Soc Sci Med. 2021;272:113688.
4. Caserotti M, Girardi P, Rubaltelli E, Tasso A, Lotto L, Gavaruzzi T. Nanoparticles and the immune system. Hum Vaccin Immunother. 2021:16(11):2586-2593.
5. Triant VA, Gandhi RT. When epidemics collide: why people with HIV may have worse COVID-19 outcomes and implications for vaccination. Clin Infect Dis. 2021:cia1946. https://doi.org/10.1093/cid/cia1946
6. Shono P, Yie X, Zou J, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. Res Sq. 2021:res.3.rs.143532. https://doi.org/10.21203/rs.3.rs.143532/v1
7. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera. bioRxiv. 2021.
8. Wang P, Liu L, Iketani S, et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv. 2021. https://doi.org/10.1101/2021.01.25.428137
9. Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021;20(1):33.
10. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Dis Discov. 2018;17(4):261-279.
11. Meyer M, Huang E, Yuzhakov O, Ramanathan P, Ciaramella G. Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from ebola virus disease. J Infect Dis. 2018;217(3):451-455.
12. Heeney A, Hand F, Bates J, Mc Cormack O, Mealy K. Surgical mortality—an analysis of all deaths within a general surgical department. Surgeon. 2014;12(3):121-128.
13. Rappuoli R, De Gregorio E, Del Giudice G, et al. Vaccinology in the post-COVID-19 era. Proc Natl Acad Sci USA. 2021;118(3):e2020368118.
14. Amanna I, Slifka MK. Public fear of vaccination: separating fact from fiction. Viral Immunol. 2005;18(2):307-315.
15. Polack FP, Thomas SJ, Kitchin N, et al. C4591001 clinical trial group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.
16. Baden LR, El Sahly HM, Essink B, et al. COVE Study Group Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416.
17. Kleine-Tebbe J, Klimek L, Hamelmann E, et al. Severe allergic reactions to the COVID-19 vaccine - statement and practical consequences. Allergol Select. 2021;5:26-28.
18. Moctan T, Matea CT, Iancu C, Agoston-Coldea L, Moctan L, Orasan R. Hypersensitivity and nanoparticles: update and research trends. Clujul Med. 2016;89(2):216-219.
19. Zolnik BS, González-Fernández A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology. 2010;151(2):458-465.
20. Bruusgaard-Mouritsen MA, Johansen JD, Garvey LH. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients. Clin Exp Allergy. 2021:cea.13822. https://doi.org/10.1111/cea.13822
21. Nikleby H. Vaccination and anaphylaxis. Curr Allergy Asthma Rep. 2006;6(1):9-13.
22. Díaz-Quijano FA. A simple method for estimating relative risk using logistic regression. BMC Med Res Methodol. 2012;12:14.
23. Fassina A, Fassan M, Dosio GB, Barzon L. Triumphs and tribulations of COVID-19 vaccines: Lessons to be learned from smallpox epidemics in the 1700s. Virchows Arch. 2021:1-3.
24. Zolk O, Bucci D, Croci R, Riccò M, Alfani P, Signorelli C. Vaccine hesitancy in COVID-19 times. An update from Italy before flu season starts. Acta Biomed. 2020;91(3):e2020031.
25. Wang K, Wong ELY, Ho KF, et al. Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: a cross-sectional survey. Vaccine. 2020;38(45):7049-7056.
26. Wang K, Wong ELY, Ho KF, et al. Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: a cross-sectional survey. Vaccine. 2020;38(45):7049-7056.
27. Odone A, Bucci D, Croci R, Riccò M, Alfani P, Signorelli C. Vaccine hesitancy in COVID-19 times. An update from Italy before flu season starts. Acta Biomed. 2020;91(3):e2020031.
28. Wang K, Wong ELY, Ho KF, et al. Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: a cross-sectional survey. Vaccine. 2020;38(45):7049-7056.
29. Kwok KO, Li KK, Wei WI, Tang A, Wong SYS, Lee SS. Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: a survey. Int J Nurs Stud. 2020;114:103854.
30. Doshi P. Will COVID-19 vaccines save lives? Current trials aren’t designed to tell us. BMJ. 2020;371:m4037.
31. Doshi P. BMJ opinion. 2021. https://blogs.bmj.com/bmj/2021/01/04/peter-doshi-pfizer-and-modernas-95-effective-vaccines-we-need-more-details-and-the-raw-data/
32. Bmj IC. India: Doctors call for investigation into allegations of ethical abuse in covid-19 vaccine trial. BMJ. 372, 2021:n131.
33. Saad N, Moussa S. Immune response to COVID-19 infection: a double-edged sword. Immunol Med. 2021:1:10.
34. Caminati M, Guarnieri G, Senna G. Who is really at risk for anaphylaxis due to COVID-19 vaccine? Vaccines. 2021;9(1):E38.
35. Kelso JM. Anaphylactic reactions to novel mRNA SARS-CoV-2/ COVID-19 vaccines. Vaccine. 2021;39:865-867.
36. Nag DS, Chaudhry R, Mishra M, Rai S, Gupta M. A prospective study on rapidly declining SARS-CoV-2 IgG antibodies within one to three months of testing IgG positive: can it lead to potential reinfections? Cureus. 2020;12(12):e11845.
37. Versteeg GA, van de Nes PS, Bredenbeek PJ, Spaan WJ. The coronavirus spike protein induces endoplasmic reticulum stress and upregulation of intracellular chemokine mRNA concentrations. J Virol. 2007;Oct 81(20):10981-10990.
38. Pum A, Ennenmoser M, Adage T, Kungl AJ. Cytokines and chemokines in SARS-CoV-2 infections-therapeutic strategies targeting cytokine storm. Biomolecules. 2021;11(1):E91.
39. McDonald CJ, Baik SH, Zheng Z, Amos L. A method for prioritizing risk groups for early SARS-CoV-2 vaccination, by the numbers. medRxiv. 2020.

How to cite this article: Chirumbolo S. Vaccination hesitancy and the “myth” on mRNA-based vaccines in Italy in the COVID-19 era: Does urgency meet major safety criteria? J Med Virol. 2021;93:4049-4053. https://doi.org/10.1002/jmv.26922